Jump to main content
Jump to site search

Issue 25, 2019
Previous Article Next Article

1,4-Anhydro-4-seleno-D-talitol (SeTal): a remarkable selenium-containing therapeutic molecule

Author affiliations

Abstract

It is well accepted that organoselenium compounds are powerful antioxidants that have potential therapeutic benefits. Unfortunately, the therapeutic value of many of these selenium-containing entities is often hampered by low solubility in aqueous solutions, which prevents them from reaching therapeutically relevant doses in plasma. We approached this problem by constructing selenosugars with infinite water solubilities. Work over many years led to the discovery of 1,4-anhydro-4-seleno-D-tallitol (SeTal), which has been shown to accelerate skin-tissue repair, heal wounds in (db/db and wt) rodent and porcine models, and prevent high-glucose-induced endothelial dysfunction in mouse aorta. This lead compound is currently being developed as a topical medicament for a variety of skin-repair scenarios. This article discusses the chemistry that led to the development of our selenium-containing carbohydrates, and showcases the remarkable therapeutic properties of SeTal.

Graphical abstract: 1,4-Anhydro-4-seleno-d-talitol (SeTal): a remarkable selenium-containing therapeutic molecule

Back to tab navigation

Publication details

The article was received on 29 Apr 2019, accepted on 28 May 2019 and first published on 04 Jun 2019


Article type: Perspective
DOI: 10.1039/C9NJ02185J
New J. Chem., 2019,43, 9759-9765

  •   Request permissions

    1,4-Anhydro-4-seleno-D-talitol (SeTal): a remarkable selenium-containing therapeutic molecule

    M. J. Davies and C. H. Schiesser, New J. Chem., 2019, 43, 9759
    DOI: 10.1039/C9NJ02185J

Search articles by author

Spotlight

Advertisements